HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

This house believes that low-dose intravenous cyclophosphamide is superior to standard high-dose regimes for treatment of lupus nephritis.

AuthorsC Gorman, A Bhatia, A Rahman (Affiliation: Centre for Rheumatology, Department of Medicine, University College of London, London, UK. clgorman at btopenworld.com)
JournalRheumatology (Oxford, England) (Rheumatology (Oxford)) Vol. 44 Issue 3 Pg. 398-401 (Mar 2005) ISSN: 1462-0324 [Print] England
PMID15494351 (Publication Type: Journal Article, Review)
Chemical References
  • Immunosuppressive Agents
  • Cyclophosphamide
Topics
  • Cyclophosphamide (administration & dosage, adverse effects)
  • Humans
  • Immunosuppressive Agents (administration & dosage, adverse effects)
  • Injections, Intravenous
  • Lupus Nephritis (drug therapy)
  • Pulse Therapy, Drug
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $45.00 USD